Biotech

A Future with Robots

September 12th, 2016

Bigger Better Faster Stronger One of the greatest strengths of the human race is our continual practice of innovation – we are always creating newer, better, faster and safer ways of completing the tasks and challenges we face. As robots have become a major topic of conversation many have begun to wonder; will robots be another success for humanity or a colossal disaster? Well, first we must determine what exactly is meant by the term robot. A robot is a […]

Read More

Biotech Firms Warn Against Changes to the R&D Tax Incentive

March 14th, 2016

There is a pervading fear in Australia that our best and brightest are failing to find opportunities locally and are instead vying for work overseas. ‘Brain Drain’, as it’s coined in public discourse, has subsequently become one of the key concerns for the Australian Government. Thus, as a response to dwindling innovation levels and in attempts to reverse the ‘brain drain’, the Australian government released the National Innovation and Science Agenda in December last year. In launching the agenda, the […]

Read More

CSL urges cuts to advanced manufacturing tax rate

August 4th, 2015

Australian biotech company CSL is calling for a lower advanced manufacturing tax rate. Last year the company decided to build a $500 million plant in Switzerland over Australia due to factors such as proximity to market, availability of staff, market experience and, specifically, a lower corporate tax rate within the country. CSL’s chief financial officer, Gordon Naylor, acknowledges tax is not the only deterrent to doing more in Australia, he says it’s a central element. That’s why CSL is pushing […]

Read More

Local Biotech firm recieves $8.8 million R&D tax offset

November 4th, 2013

Alchemia (ASX:ACL) has received an additional $8.8 million rebate as part of the R&D Tax Incentive Scheme. The new rebate for FY13 brings the total funds Alchemia has received under the R&D incentive scheme over the last 12 months to over $13 million. In December, Alchemia won approval from AusIndustry to apply for incentive credits for non-Australian R&D conducted by business unit Alchemia Oncology. In a filing, the company said its FY13 rebate includes claims from both overseas and domestic R&D, […]

Read More

Categories

Archives

    Email this job